Jimmy Dikeakos

Dr. Jimmy Dikeakos


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2016 in Scientific Reports
Verified
Journal Article
Open access
BDBrennan S. Dirk
Brennan S. Dirk
EPEmily N. Pawlak
Emily N. Pawlak
AJAaron L. Johnson
Aaron L. Johnson
LNLogan R. Van Nynatten
Logan R. Van Nynatten
RJRajesh A. Jacob
Rajesh A. Jacob
JDJimmy Dikeakos
Jimmy Dikeakos
A defining characteristic of HIV-1 infection is the ability of the virus to persist within the host. Specifically, MHC-I downregulation by the HIV-1 accessory protein Nef is of critical importance in preventing infected cells from cytotoxic T-cell mediated killing. Nef downregulates MHC-I by modulating the host membrane trafficking machinery, resulting in the endocytosis and eventual sequestration of MHC-I within the cell. In the current report, we utilized the intracellular protein-protein interaction reporter system, bimolecular fluorescence complementation (BiFC), in combination with super-resolution microscopy, to track the Nef/MHC-I interaction and determine its subcellular localization in cells. We demonstrate that this interaction occurs upon Nef binding the MHC-I cytoplasmic tail early during endocytosis in a Rab5-positive endosome. Disruption of early endosome regulation inhibited Nef-dependent MHC-I downregulation, demonstrating that Nef hijacks the early endosome to sequester MHC-I within the cell. Furthermore, super-resolution imaging identified that the Nef:MHC-I BiFC complex transits through both early and late endosomes before ultimately residing at the trans-Golgi network. Together we demonstrate the importance of the early stages of the endocytic network in the removal of MHC-I from the cell surface and its re-localization within the cell, which allows HIV-1 to optimally evade host immune responses.

1 April 2015 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
EPEmily N. Pawlak
Emily N. Pawlak
JDJimmy Dikeakos
Jimmy Dikeakos

14 February 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
ETElena Tutunea-Fatan
Elena Tutunea-Fatan
SAShabitha Arumugarajah
Shabitha Arumugarajah
RSRita S. Suri
Rita S. Suri
CECassandra R. Edgar
Cassandra R. Edgar
IHIngrid Hon
Ingrid Hon
LGLakshman Gunaratnam
Lakshman Gunaratnam
Kidney injury molecule-1 (KIM-1), also known as T-cell Ig and mucin domain-1 (TIM-1), is a widely recognized biomarker for AKI, but its biological function is less appreciated. KIM-1/TIM-1 belongs to the T-cell Ig and mucin domain family of conserved transmembrane proteins, which bear the characteristic six-cysteine Ig-like variable domain. The latter enables binding of KIM-1/TIM-1 to its natural ligand, phosphatidylserine, expressed on the surface of apoptotic cells and necrotic cells. KIM-1/TIM-1 is expressed in a variety of tissues and plays fundamental roles in regulating sterile inflammation and adaptive immune responses. In the kidney, KIM-1 is upregulated on injured renal proximal tubule cells, which transforms them into phagocytes for clearance of dying cells and helps to dampen sterile inflammation. TIM-1, expressed in T cells, B cells, and natural killer T cells, is essential for cell activation and immune regulatory functions in the host. Functional polymorphisms in the gene for KIM-1/TIM-1, HAVCR1, have been associated with susceptibility to immunoinflammatory conditions and hepatitis A virus–induced liver failure, which is thought to be due to a differential ability of KIM-1/TIM-1 variants to bind phosphatidylserine. This review will summarize the role of KIM-1/TIM-1 in health and disease and its potential clinical applications as a biomarker and therapeutic target in humans.

17 March 2020 in Journal of Virology
Verified
Journal Article
Closed access
JPJérémie Prévost
Jérémie Prévost
CECassandra R. Edgar
Cassandra R. Edgar
JRJonathan Richard
Jonathan Richard
STSteven M. Trothen
Steven M. Trothen
RJRajesh Abraham Jacob
Rajesh Abraham Jacob
JDJimmy Dikeakos
Jimmy Dikeakos
HIV infection modulates the surface expression of Tim-3, but the molecular determinants remain poorly understood. Here, we show that HIV-1 Vpu downregulates Tim-3 from the surface of infected primary CD4 + T cells through its transmembrane domain and alters its subcellular localization. Tim-3 blockade increases HIV-1 replication, suggesting a potential negative role of this protein in viral spread that is counteracted by Vpu.

12 January 2018 in Retrovirology
Verified
Journal Article
Open access
PDF file
EPEmily N. Pawlak
Emily N. Pawlak
BDBrennan S. Dirk
Brennan S. Dirk
RJRajesh Abraham Jacob
Rajesh Abraham Jacob
AJAaron L. Johnson
Aaron L. Johnson
JDJimmy Dikeakos
Jimmy Dikeakos
The HIV-1 accessory proteins Nef and Vpu alter cell surface levels of multiple host proteins to modify the immune response and increase viral persistence. Nef and Vpu can downregulate cell surface levels of the co-stimulatory molecule CD28, however the mechanism of this function has not been completely elucidated. Here, we provide evidence that Nef and Vpu decrease cell surface and total cellular levels of CD28. Moreover, using inhibitors we implicate the cellular degradation machinery in the downregulation of CD28. We shed light on the mechanisms of CD28 downregulation by implicating the Nef LL165 and DD175 motifs in decreasing cell surface CD28 and Nef DD175 in decreasing total cellular CD28. Moreover, the Vpu LV64 and S52/56 motifs were required for cell surface CD28 downregulation, while, unlike for CD4 downregulation, Vpu W22 was dispensable. The Vpu S52/56 motif was also critical for Vpu-mediated decreases in total CD28 protein level. Finally, the ability of Vpu to downregulate CD28 is conserved between multiple group M Vpu proteins and infection with viruses encoding or lacking Nef and Vpu have differential effects on activation upon stimulation. We report that Nef and Vpu downregulate cell surface and total cellular CD28 levels. We identified inhibitors and mutations within Nef and Vpu that disrupt downregulation, shedding light on the mechanisms utilized to downregulate CD28. The conservation and redundancy between the abilities of two HIV-1 proteins to downregulate CD28 highlight the importance of this function, which may contribute to the development of latently infected cells.

28 February 2023 in Journal of Virology
Verified
Journal Article
Open access
FGFelicia Goodrum
Felicia Goodrum
ALAnice C. Lowen
Anice C. Lowen
Seema  LakdawalaSeema Lakdawala
Seema Lakdawala
JAJames Alwine
James Alwine
ACArturo Casadevall
Arturo Casadevall
AYAndrew Yurochko
Andrew Yurochko
Viruses have brought humanity many challenges: respiratory infection, cancer, neurological impairment and immunosuppression to name a few. Virology research over the last 60+ years has responded to reduce this disease burden with vaccines and antivirals.